Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Expands To 137 Issued Patents For Hypertension and Heart Failure Treatment

Orchestra BioMed Holdings, Inc., a biomedical company focused on accelerating innovative technologies to patients through risk-reward sharing partnerships, has announced the continued expansion of its global intellectual property (IP) portfolio supporting its proprietary AVIM therapy pipeline, formerly known as Cardiac Neuromodulation Therapy (CNT). Over the past year, the company has secured 10 new patents related to the treatment of hypertension. Additionally, it has obtained 17 patents for the use of the technology in treating heart failure, significantly broadening the scope of its IP platform.

AVIM therapy is currently being tested in the BACKBEAT global pivotal study, aimed at treating uncontrolled hypertension in patients who have or are expected to receive a pacemaker. This patient group represents a broader population of individuals with high blood pressure who are at greater risk for severe cardiovascular events and related conditions, such as heart attacks, strokes, and heart failure. This highlights the potential of AVIM therapy to make a significant impact on cardiovascular health, extending beyond just blood pressure management.

David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, mentioned, “We are very proud of the continued expansion of our intellectual property portfolio supporting AVIM therapy, which we are actively evaluating for the treatment of hypertension in the BACKBEAT global pivotal study in collaboration with Medtronic. Over the past year, we have strengthened our patent estate with ten newly issued patents covering the treatment of hypertension. Our issued hypertension-specific patent portfolio is now 120 patents strong and we expect it to continue to grow in the future.”

Discover Why Dr. Reddy Was Chosen to Lead BACKBEAT

He continued, “Equally exciting is our growing heart failure treatment patent estate which now comprises seventeen issued patents. This extraordinary array of intellectual property reflects our strategic commitment to protect our proprietary, high-impact device-based therapy which we believe can help physicians better address the needs of patients with hypertension, the leading global risk factor for death, as well as heart failure, which affects more than 64 million people worldwide.”

Recently, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to AVIM therapy for treating uncontrolled hypertension with increased cardiovascular risk, regardless of the need for a pacemaker. Orchestra BioMed’s global IP portfolio for AVIM therapy includes patent protection in key markets, including the United States, Europe, Japan, and China, ensuring broad protection for its innovative approach to treating hypertension and heart failure.